Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Crinetics Pharmaceuticals — Total liabilities by Quarter
Crinetics Pharmaceuticals — Total liabilities ($M) ($M)
Vertex Pharmaceuticals Crinetics Pharmaceuticals — Total liabilities: $130M in Q2 2026, up 10.1% from a year earlier.
Where the Q2 2026 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Crinetics Pharmaceuticals — Total liabilities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 130 | +10.1% | SEC Filing ↗ |
| Q1 2026 | Mar 31, 2026 | 121 | +12.4% | SEC Filing ↗ |
| Q4 2025 | Dec 31, 2025 | 134 | +22.2% | SEC Filing ↗ |
| Q3 2025 | Sep 30, 2025 | 124 | +18.7% | SEC Filing ↗ |
| Q2 2025 | Jun 30, 2025 | 118 | +12.7% | SEC Filing ↗ |
| Q1 2025 | Mar 31, 2025 | 107 | +4.0% | SEC Filing ↗ |
| Q4 2024 | Dec 31, 2024 | 110 | +14.1% | SEC Filing ↗ |
| Q3 2024 | Sep 30, 2024 | 104 | +11.3% | SEC Filing ↗ |
| Q2 2024 | Jun 30, 2024 | 105 | +167.7% | SEC Filing ↗ |
| Q1 2024 | Mar 31, 2024 | 103 | +206.5% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 96.3 | +168.5% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 93.8 | +179.9% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 39.1 | +10.0% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 33.7 | +11.4% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 35.9 | +88.0% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 33.5 | +112.5% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 35.6 | +129.6% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 30.2 | +114.9% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 19.1 | +31.2% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 15.8 | +20.5% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 15.5 | +7.9% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 14.1 | -8.9% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 14.5 | +9.7% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 13.1 | +0.8% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 14.4 | +10.0% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 15.5 | +7.5% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 13.2 | +18.3% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 13.0 | +41.8% | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 13.1 | +89.1% | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 14.4 | – | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | 11.2 | – | SEC Filing ↗ |
| Q3 2018 | Sep 30, 2018 | 9.16 | – | SEC Filing ↗ |
| Q2 2018 | Jun 30, 2018 | 6.90 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals — Total liabilities ($M), quarterly Q2 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-liabilities
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.